Skip to content
Screener

Theravance Biopharma TBPH Q1 2025 earnings

Reported May 8, 2025 · After market close

Revenue$15.4MMiss by $712.0K
EPS-$0.17Miss by $0.06
Revenue estimate$16.1M
EPS estimate-$0.11

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$22.0M
EPS estimate$0.24

Financials

Q1 2025

Income statement

See full
Revenue$15.4M+6.1%
Operating income-$14.4M-28.8%
Net income-$13.6M-16.4%
EPS (diluted)-$0.27-12.5%

Balance sheet

See full
Cash & equivalents$110.6M+105%
Total debt$48.2M+0.5%
Total equity$166.0M-19.0%
Total assets$343.6M-7.5%

Cash flow

See full
Operating cash flow$43.0M+4,311%
Free cash flow$59.6M+5,457%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$441.77M-0.3%
Enterprise value$379.31M-13.3%
P/S6.8×-0.4×

Profitability

See full
Operating margin-76.9%+10.2pp
Net margin-89.4%+26.4pp
FCF margin74.9%+58.2pp

Returns & leverage

See full
Return on equity-31.5%-1,478pp
Debt / equity0.3×+0.1×
Current ratio4.8×-1.0×

Segments

By segment

See full
Single Reportable$15.4M+6.1%

By product

See full
Collaborative Arrangement Revenue$15.4M+6.1%

FAQ

When did Theravance Biopharma report Q1 2025 earnings?
Theravance Biopharma (TBPH) reported Q1 2025 earnings on May 8, 2025 after market close.
What were Theravance Biopharma's Q1 2025 revenue and EPS?
Theravance Biopharma reported revenue of $15.4M and eps of $-0.17 for Q1 2025.
Did Theravance Biopharma beat estimates in Q1 2025?
Revenue missed the consensus estimate of $16.1M by $712.0K. EPS missed the consensus estimate of $-0.11 by $0.06.
How did Theravance Biopharma's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 6.1% from $14.5M a year earlier and eps declined 88.9% from $-0.09.
Where can I find Theravance Biopharma's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-046137) and the 10-Q periodic report (0001558370-25-007398) directly on SEC EDGAR. The filing index links above go to sec.gov.